FDA Grants Approval for Cabozantinib in Advanced Neuroendocrine Tumors

The U.S. Food and Drug Administration (FDA) has officially approved cabozantinib (marketed as Cabometyx), an oral medication classified as a tyrosine kinase inhibitor. This approval is specifically for patients with advanced neuroendocrine tumors who have previously received treatment, marking a significant advancement in therapeutic options for this demographic.

This landmark decision follows the positive outcomes derived from the phase 3 CABINET study, which evaluated the efficacy of cabozantinib against a placebo in patients with advanced pancreatic neuroendocrine tumors and advanced extrapancreatic neuroendocrine tumors. The findings of this pivotal trial were published in the New England Journal of Medicine last September.

Results indicated that patients administered cabozantinib experienced markedly longer survival rates without disease progression compared to those receiving the placebo. The study was unblinded and terminated early in August 2023 due to the promising interim results, highlighting the drug's potential to significantly enhance patient outcomes.

Common side effects associated with cabozantinib were found to align with previous studies, including hypertension, fatigue, and diarrhea, which are important considerations for both healthcare providers and patients.

According to the lead investigator of the CABINET study, there is a pressing need for new and effective treatment options for patients dealing with neuroendocrine tumors. The approval of cabozantinib offers renewed hope for patients whose cancer has either progressed or metastasized. The FDA's endorsement of cabozantinib thus represents a pivotal development in the fight against these challenging tumors.

This approval has been granted to Exelixis, the manufacturer of cabozantinib.